Highlights Molecure S.A.

Equities

MOC

PLONCTH00011

Delayed Warsaw S.E. Other stock markets 11:33:31 29/05/2024 BST			5-day change	1st Jan Change
14.92 ^PLN	-0.53%		-3.24%	-23.49%

05-17	Molecure S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
03-22	Molecure S.A. Announces First Patient in the OATD-01 Phase 2 KITE Study in Pulmonary Sarcoidosis	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Molecure S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-17	CI
Molecure S.A. Announces First Patient in the OATD-01 Phase 2 KITE Study in Pulmonary Sarcoidosis	03-22	CI
Molecure S.A Announces No Grant of Permission to Conduct Phase II Clinical Trials for the OATD-01 Molecule I	01-16	CI
Molecure S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	30/10/23	CI
Molecure S.A. Reports Earnings Results for the Half Year Ended June 30, 2023	28/09/23	CI
Poland's Molecure Gets US FDA Clearance for Mid-stage Trial of Potential Pulmonary Sarcoidosis Treatment	24/07/23	MT
Molecure S.A. Receives Clearance from the U.S. Food and Drug Administration on its Investigational New Drug Application to Conduct Phase II Clinical Testing of OATD-01	24/07/23	CI
Molecure S.A. Reports Earnings Results for the First Quarter Ended March 31, 2023	27/04/23	CI
Molecure S.A. Reports Earnings Results for the Full Year Ended December 31, 2022	29/03/23	CI
Molecure Announces First Patient Dosed in Phase I Trial with Novel, First-In-Class Dual Arginase Inhibitor OATD-02 for the Treatment of Cancer	08/03/23	CI
Molecure S.A. to Begin Clinical Development of Novel Dual Arginase Inhibitor Oatd-02 for the Treatment of Cancer After Gaining Permission to Conduct First Clinical Trial in Poland	28/11/22	CI
Molecure S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	30/10/22	CI
Molecure S.A. Reports Earnings Results for the Half Year Ended June 30, 2022	28/09/22	CI
Molecure S.A. Reports Earnings Results for the First Quarter Ended March 31, 2022	28/04/22	CI
OncoArendi Therapeutics S.A. Announces A License Option Agreement with University of Michigan	11/03/22	CI
OncoArendi Therapeutics S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	28/10/21	CI
OncoArendi Therapeutics SA and Galapagos Enter into Exclusive Collaboration on Chitinase Inhibitors in Fibrosis	05/11/20	CI
Oncoarendi Therapeutics S.A. Reports Earnings Results for the Third Quarter Ended September 30, 2020	30/10/20	CI
Oncoarendi Therapeutics S.A. Reports Earnings Results for the Half Year Ended June 30, 2020	24/09/20	CI
OncoArendi Therapeutics S.A. has completed an IPO in the amount of PLN 58 million.	04/04/18	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Molecure S.A.

Equities

MOC

PLONCTH00011

Highlights

Filters